Scarica l'app Stockscreener
2.05
5.53%
-0.12
Dopo l'orario di chiusura:
2.15
0.10
+4.88%
Precedente Chiudi:
$2.17
Aprire:
$2.21
Volume 24 ore:
440.44K
Relative Volume:
1.02
Capitalizzazione di mercato:
$56.12M
Reddito:
-
Utile/perdita netta:
$-40.94M
Rapporto P/E:
-0.5339
EPS:
-3.84
Flusso di cassa netto:
$-22.97M
1 W Prestazione:
-21.15%
1M Prestazione:
+0.49%
6M Prestazione:
-61.10%
1 anno Prestazione:
-65.83%
Intervallo 1D:
$2.05
$2.21
Intervallo di 1 settimana:
$2.05
$3.18
Portata 52W:
$1.11
$17.88
Annovis Bio Inc Stock (ANVS) Company Profile
Nome
Annovis Bio Inc
Settore
Industria
Telefono
484-875-3192
Indirizzo
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Confronta ANVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.05 | 56.12M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Aggiornamento | Maxim Group | Hold → Buy |
| 2023-12-29 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
Annovis Bio Inc Borsa (ANVS) Ultime notizie
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - MSN
HC Wainwright Has Optimistic View of Annovis Bio Q2 Earnings - Defense World
Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Annovis Bio (NYSE:ANVS) Price Target Cut to $12.00 by Analysts at HC Wainwright - Defense World
Annovis Bio (ANVS) Price Target Cut by 60% by HC Wainwright | AN - GuruFocus
Annovis Bio stock price target cut to $12 at H.C. Wainwright By Investing.com - Investing.com South Africa
Annovis Bio stock price target cut to $12 at H.C. Wainwright - Investing.com Nigeria
Annovis Bio (ANVS) Price Target Slashed by H.C. Wainwright | ANVS Stock News - GuruFocus
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MSN
Annovis Bio Inc. to Host Webcast on Alzheimer’s and Parkinson’s Programs Updates - citybuzz -
Annovis to Host Webinar and Live Q&A on June 24, 2025 - GlobeNewswire
Annovis Bio, Inc. to Host Live Webcast on Neurodegenerative Disease Developments and Phase 3 Trial Updates - Nasdaq
Annovis CEO Reveals Latest Alzheimer's Phase 3 Data and FDA Feedback on Parkinson's Program - Stock Titan
Annovis Bio (ANVS) Stock Surges Over 28% | ANVS Stock News - GuruFocus
Northern Trust Corp Acquires 10,846 Shares of Annovis Bio, Inc. (NYSE:ANVS) - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Shares Purchased by Jane Street Group LLC - Defense World
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021 - The Globe and Mail
Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN
Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus
Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia
Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus
Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - The Manila Times
Annovis Bio Appoints New Principal Financial Officer - TipRanks
Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com
Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq
Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World
Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN
Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -
Annovis Bio hires new director of biostatistics amid AD trial - Investing.com
Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com
Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan
LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Annovis Bio Inc Azioni (ANVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):